ArticleFrontiers in medicine2026
Incidence trends of aplastic anaemia in Kazakhstan: a nationwide study (2014-2024).
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aplastic anaemia (AA) is a rare hematologic disorder with substantial morbidity and mortality. Limited data are available on its epidemiology in Central Asia, including Kazakhstan. Objective: To analyze temporal trends and regional variation in the incidence of AA in Kazakhstan from 2014 to 2024. Methods: A retrospective population-based longitudinal study was conducted using national electronic medical records. Incident cases of AA were identified using ICD-10 code D61 and categorized as idiopathic/unspecified or secondary. Incidence rates per 100,000 population were calculated annually and analyzed by region and disease subtype. Descriptive statistics were used to summarize demographic and clinical characteristics. Results: A total of 1,209 incident cases were identified during the study period. The median age was 26 years, with a slight female predominance (52.3%). Most cases were classified as idiopathic or unspecified (88.9%). The national incidence of AA increased from 0.21 per 100,000 population in 2014 to 0.82 per 100,000 in 2024. This increase was primarily driven by idiopathic cases, while secondary AA remained relatively stable and uncommon. Regional variation was observed, with the highest incidence in major urban centers (up to 1.48 per 100,000 in 2024), whereas other regions ranged from 0.3 to 0.9 per 100,000. Conclusion: The incidence of AA in Kazakhstan has increased over the past decade, largely due to a rise in idiopathic cases. Geographic disparities suggest differences in healthcare access and diagnostic capacity. Strengthening surveillance systems and improving equitable access to specialized care are essential for better detection and management of AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.